🦴 #BoneHealth in newly diagnosed female #BreastCancer patients in China 🇨🇳

❗ 63.2% have Abnormal Bone Mass
🔺 92.3% with Vitamin D deficiency
⚠️ 5.5x ⬆️ risk of ABM in BC 🆚 controls
🧑‍⚕️ Young BC patients (<45) 9x higher risk

@oncoalert.bsky.social @nature.com

👉 nature.com/articles/s41598-024-84698-1

Urinary DNA methylation test:

✅89% sensitivity for high-grade or invasive #BladderCancer‼️
✅Outperforms NMP22 & urine cytology tests with high specificity
✅Excellent negative predictive value
🔽Suboptimal positive predictive value

@oncoalert.bsky.social

jamanetwork.com/journals/jam...

💫 Phase 3 #KEYNOTE756 trial - 1⃣st interim analysis: 💫

✅ Pembro + chemo ⬆️ pCR in high-risk early ER+/HER2− #BreastCancer (24.3% 🆚 15.6%)
⚠️ Manageable safety
📊 EFS data maturing
📰 Read more: nature.com/articles/s41...
@oncoalert.bsky.social

Dear Colleagues,

Don’t miss #OncoAlertColloquium & our #BreastCancer Faculty: brilliant dr Matteo Lambertini 🇮🇹, presenting on #FertilityPreservation (year in review) on February 5, 2025.

REGISTER for FREE HERE
👉 buff.ly/3CChgre

@oncoalert.bsky.social

This article explores the social, psychological & cognitive factors contributing to overtreatment at the #EOL and strategies to address them. @oncoalert.bsky.social

www.esmoopen.com/article/S205...

Final OS analysis from #FALCON:

✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC

✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)

@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…

🆕 data from KATHERINE trial confirms T-DM1 improves OS & sustains IDFS in HER2+ early #BreastCancer with residual disease after neoadjuvant therapy.

7-year IDFS: 80.8% (T-DM1) 🆚 67.1% (trastuzumab)
7-year OS: 89.1% (T-DM1) 🆚 84.4% (trastuzumab)

@oncoalert.bsky.social
nejm.org/doi/full/10.10…

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...

On January 17, 2025🚨FDA approved☑️datopotamab deruxtecan-dlnk for unresectable/ metastatic, HR-positive, HER2-negative #BreastCancer 🎀who have received prior endocrine and chemotherapy for unresectable/metastatic disease. 🍀 #Oncology #FDAapproval
@oncoalert.bsky.social

www.fda.gov/drugs/resour...

Intratumoral💉#pembrolizumab & mRNA-2752 for high-risk #DCIS : Phase 1 nonrandomized trial

✅80% response rate
❌no major systemic toxicities
✅ complete tumor resolution in some➡️possible surgery reduction
🎀 ongoing studies needed
@oncoalert.bsky.social
@jama.com

shorturl.at/W7pU2

Review of🔑clinical trials in #CRC in 2024

KRYSTAL-1: Adagrasib + cetuximab approved as 1⃣st KRAS G12C therapy for mCRC
TransMet: survival benefits after liver transplant in liver-only mCRC
NICHE-2: 95% major pathologic response with nivolumab + ipilimumab in dMMR colon cancer
@oncoalert.bsky.social

Ultrasensitive ctDNA 🧬detection for pre-op stratification in early LUAD 🫁: Analysis from #TRACERx :

buff.ly/4jl6fLR

🧬NeXT Personal detects #ctDNA in 81% pre-op LUAD 🫁, even in stage I.
🧬ctDNA <80 ppm predicts worse outcomes🆚ctDNA-negative cases.
#LungCancer

Thank you so much, Kate! 🌹

Weight Changes and Heart Failure After Breast Cancer This cohort study assesses the role of postdiagnosis and prediagnosis in weight gain in individuals with higher risk for cardiac dysfunction.

🫀dysfunction, including heart failure, is a ⬆️concern for #BreastCancerSurvivors due to cardiotoxic therapy like anthracyclines & trastuzumab.

A Korean study shows that
⬆️weight gain after a #BC diagnosis ⬆️ risk of heart failure💔

@oncoalert.bsky.social @jama.com
ja.ma/42eruIO

Thrilled to share that after an incredible mentorship experience with Prof. Matteo Lambertini last year, I’ve been selected for the 2025 ESO mentorship program!🌟This year, I have the honor of being mentored by Prof. Bostjan Seruga. 🙌
Excited for the journey ahead! 😊😊😊 @oncoalert.bsky.social

🌟 #Supponc systematic review highlights the 🔼 use of #AI 🤖 in symptom prediction & monitoring for adult #CancerSurvivors.
Pain, fatigue & nausea are🔑symptoms monitored with #AI tools like machine learning & NLP, revolutionizing patient care. 🌟
@oncoalert.bsky.social

👉 shorturl.at/vdKKQ

🌟Exploring neoadjuvant therapy for occult #BreastCancer with axillary presentation, a retrospective study of 114 patients suggests that targeted axillary surgery may be considered instead of axillary dissection in select cases. 🌟

Read more 👉 buff.ly/3Wfs9WI
#Oncology #OncoAlertAF

Eribulin combined with trastuzumab & pertuzumab shows potential to become the🆕standard in 1️⃣st-line treatment for HER2+ locally advanced/metastatic #BreastCancer. Results from the phase III EMERALD trial suggest comparable efficacy to taxanes, with improved QoL.

👉 buff.ly/4hfnuMJ

Study of 542,778 women in the UK (16.6 yrs, 12,251 cases) links diet to #ColorectalCancer risk:

🔺 Higher risk: 🍷Alcohol &🥩 Red/processed meat

🔻 Protective:
🥛 Dairy (calcium)
🌾 Wholegrains & fiber
🍎 Fruits &🍳Cereal
🍋 Vitamin C &🥬Folate
🍚 Carbs

Read more 👉 buff.ly/40eEVGd
@oncoalert.bsky.social

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase II... PURPOSETrastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninfer...

🌟EMERALD: Eribulin + HP is an option for 1️⃣st-line treatment of locally advanced/metastatic HER2+ #BreastCancer :

✅ Noninferior efficacy to taxane

✅Toxicity differences:
⬇️ infusion reactions, diarrhea, and edema
⬆️ neutropenia

@oncoalert.bsky.social @JCO_ASCO
ascopubs.org/doi/10.1200/...

Dear colleagues,
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈

📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology

Don’t miss this unique #oncology event! 🌍👩‍⚕️👨‍⚕️

@oncoalert.bsky.social #OncoAlertAF

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | NEJM Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive uro...

✨AMBASSADOR✨: Adjuvant #Pembrolizumab🆚 Observation in Muscle-Invasive Urothelial Carcinoma
🕒FU: Median 44.8 months
📈DFS: 29.6 months (Pembro) 🆚 14.2 months (Obs) HR 0.73 (p=0.003)
⚠️AEs G≥3: 50.6% (Pembro) vs 31.6% (Obs)
@oncoalert.bsky.social @nejm.org
👉 www.nejm.org/doi/full/10....

⏳Delayed nephrectomy in #mRCC pts with CR/mPR after #immunotherapy shows🍀promising outcomes (48% progression-free at 29.6 months) but comes with ⬆️ surgical complexity - 65.7% cases faced challenges when tumor downsizing >10%.

👉 link.springer.com/article/10.1...

@oncoalert.bsky.social #OncoAlertAF

🚨The @oncoalert.bsky.social Video Journal 🚨

🌟This week, our #OncoAlertAF colleague @biagioricciutimd.bsky.social guides us through his paper in @jama.com:Deep Learning Model for Predicting Immunotherapy Response in Advanced Non–Small Cell Lung Cancer

🎥 Watch the highlights 👇

💡CMG901, the 1️⃣st #ADC targeting Claudin 18.2, demonstrated promising antitumor activity in a phase 1 trial in patients with advanced #gastric and #GEJ cancers:

⚠️Common AEs were vomiting, anorexia, proteinuria, anemia (Gr ≥3 in 68%)

Read more: buff.ly/3PmhYfk

💡Great overview of the role of #immunotherapy in advanced #LUSC 🫁and the remaining questions: optimizing regimens, identifying robust biomarkers, and exploring emerging strategies like💉next-generation ICIs, bispecific antibodies and personalized vaccines.
#Oncology

Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma - Breast Cancer Research and Treatment Purpose Due to biological heterogeneity of breast carcinoma, predicting the individual response to neoadjuvant treatment (NAT) is complex. Consequently, there are no comprehensive, generally accepted ...

🌟Study of 257 Finnish #BreastCancer pts identified🔑predictive factors for response to neoadjuvant therapy. @springernature.bsky.social
Key findings:
⚠️⬇️ PR = 3.8x⬆️mortality risk
Personalized, risk-adapted surveillance & treatment is crucial!
@oncoalert.bsky.social
link.springer.com/article/10.1...

✨C9741 trial 12-year FU insights in @JCO_ASCO:

Dose-dense chemo shows sustained benefit in N+ #BreastCancer
📈+23% DFS (HR 0.77)
📈+20% OS (HR 0.80)

🔬Low SET2,3 biomarker = biggest benefit in ER+

❌Tumor burden, molecular subtype, menopausal status ≠ predictive

@oncoalert.bsky.social
rb.gy/gyi9jm

🆕study in Nature Cancer uncovers how circulating tumor cell (#CTC) plasticity drives therapy resistance in metastatic #breastcancer via the NRG1–HER3 axis. Dual blockade of 🎯 NRG1–HER3 & FGFR1 signaling offers a path to #PrecisionMedicine.
Read more: buff.ly/3Pniny0

🎀January is #CervicalCancerAwarenessMonth🎀

💡 #Prevention saves lives:
✅ #HPV vaccine: Effective protection against the cause
✅ Regular screenings - early detection: PAPA test & HPV test
✅ Treatment of precancerous lesions

@oncoalert.bsky.social
#CervicalCancer #Oncology

Camrelizumab vs Placebo With Chemotherapy as Neoadjuvant Treatment in Triple-Negative Breast Cancer This phase 3 randomized clinical trial examines the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for patients with triple-negative ...

🌟 CamRelief Trial:
Camrelizumab + chemo 🆚 placebo + chemo in early/locally advanced #TNBC patients:

✅ pCR:
📈 56.8% with camrelizumab 🆚 44.7% with placebo (Δ +12.2%)

💡Neoadjuvant anti–PD-1 strategy shows promise!🍀

@oncoalert.bsky.social #oncology #Immunotherapy

jamanetwork.com/journals/jam...